Avadel Pharmaceuticals Announces Data Supporting Clinical Profile for LUMRYZ™ at SLEEP 2023 streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
– 12 accepted abstracts highlight Company’s emerging leadership in narcolepsy – – Data adds to growing body of evidence demonstrating positive clinical benefit and patient. | June 10, 2023
The FDA has granted final approval to Lumryz (sodium oxybate) for the treatment of cataplexy or excessive daytime sleepiness in adults with narcolepsy.